Search This Blog

Friday, January 17, 2025

The Magic Of China's Ridiculous GDP: It's An Input, Not An Output

 By Stefan Koopman, Senior Macro Strategist at Rabobank

An Input, Not An Output

China just hit its 2024 growth target, as it always does. According to Bloomberg, an “11th-hour stimulus blitz” and “some export boom turbocharged activity” were required to get it over the line, but here we are. Gross domestic product rose 5.0%, exceeding forecasts of 4.9% growth. The December data showed a rapid rise in industrial production, up 6.2%, with some tentative signs that domestic demand is picking up as well. Retail sales rose 3.8% in the last quarter, its fastest pace in 2024. That said, its trade surplus surged to nearly $1 trillion last year – roughly the size of Poland’s entire economy. That means China needs the rest of the world for its growth; not the other way around.

Growth for 2025 is targeted at 5% again. Of course, we all pretend to forecast it as if it may not happen, but in China, GDP is an input, not an output. The global consensus among policymakers and analysts is that China will have to pivot from its export-dependent, investment-heavy growth model toward one centered on domestic consumption. Yet, this structural shift remains constrained by the ideological preferences of Chinese leadership, which continues to prioritize state-driven economic strategies. Even so, there are some indications of rebalancing. Money supply growth appears to be stabilizing, and after three consecutive years of contraction, the real estate sector may have bottomed. However, policy efforts to bolster consumer spending tend to underwhelm, contributing to uncertainty on how that 5% target will actually be achieved.

Meanwhile, in the U.S., economic data was mixed. Jobless claims edged slightly above expectations, while retail sales underwhelmed. However, control-group sales – the metric feeding directly into GDP – rose faster than forecast, contributing to a modest uptick in the Atlanta Fed’s Nowcast for Q4 GDP, which now projects a 3.0% annualized growth rate. Despite this, the data lacked the heft to prompt a significant market reaction, especially compared to Wednesday’s exuberance when both stocks and bonds rallied after a small beat in core inflation.

More notably, the Philly Fed survey surprised with a headline reading of 44.3, its highest since April 2021 and the largest positive surprise since 1998. This could reflect tariff-related front-loading activity, as such a surprise is otherwise hard to rationalize, but it may be mirrored in the January Manufacturing ISM.

Treasury yields eventually did fell another 2-4 basis points across the curve. This followed comments from the Fed’s Waller, who said the FOMC could lower rates more and sooner should inflation data continue to be favorable in the months ahead. His remarks threw a bit of cold water on the narrative that the Fed may be done cutting rates.

And then there was Trump’s Treasury pick, Scott Bessent, who had his hearing. He stated that the FOMC should remain independent, vowed to protect the USD’s status as the world’s reserve currency, loathed for China’s export-dependent growth model, advocated for ramping up sanctions on Russia, and pledged to work across the aisle to remove the debt ceiling if that’s what Trump wants. Additionally, he said he wants to prioritize extending the Tax Cuts and Jobs Act, while cutting the deficit by slashing discretionary spending.

https://www.zerohedge.com/markets/magic-chinas-ridiculous-gdp-its-input-not-output

Trump Orders Inauguration Moved Indoors Due To 'Dangerous Conditions'

 President-elect Donald Trump has ordered Monday's inauguration to be moved indoors.

In a post to Truth Social, Trump said that the weather forecast, including "the windchill factor, could take temperatures into severe record lows."

"There is an Arctic blast sweeping the Country. I don't want to see people hurt, or injured, in any way," Trump's post continued, adding "Therefore, I have ordered the Inauguration Address, in addition to prayers and other speeches, to be delivered in the United States Capitol Rotunda, as was used by Ronald Reagan in 1985."

So basically this:

Ronald Reagan inauguration, 1985

Of course, it may be the weather, or it may be something else. As Rep. Marjorie Taylor Greene opined on X, "I have personally attended countless rallies where President Trump spoke in extreme weather conditions from cold to rain to heat," adding "Is there a security threat other than extreme cold temperatures?"

https://www.zerohedge.com/political/trump-orders-inauguration-moved-indoors-due-dangerous-conditions

Novo Nordisk A/S: Semaglutide 7.2 mg s.c. achieved 20.7% weight loss in the STEP UP obesity trial

 Novo Nordisk today announced headline results from STEP UP, a phase 3b trial in the global STEP programme. STEP UP is a 72-week efficacy and safety trial investigating subcutaneous semaglutide 7.2 mg compared to semaglutide 2.4 mg and placebo, all administered once weekly. The trial included 1,407 randomised adults with obesity. All treatment arms were in conjunction with lifestyle intervention.

The trial achieved its primary endpoint by demonstrating a statistically significant and superior weight loss at week 72 with semaglutide 7.2 mg versus placebo.

When evaluating the effects of treatment if all people adhered to treatment1 from a mean baseline body weight of 113 kg, people treated with semaglutide 7.2 mg achieved a superior weight loss of 20.7% after 72 weeks compared to a reduction of 17.5% with semaglutide 2.4 mg and 2.4% with placebo. In addition, 33.2% of those who received semaglutide 7.2 mg achieved a weight loss of 25% or more after 72 weeks, compared to 16.7% with semaglutide 2.4 mg and 0.0% with placebo.

When applying the treatment policy estimand2, people treated with semaglutide 7.2 mg achieved a superior weight loss of 18.7% compared to a reduction of 15.6% with semaglutide 2.4 mg and 3.9% with placebo.

In the trial, semaglutide 7.2 mg appeared to have a safe and well-tolerated profile. The most common adverse events were gastrointestinal, and the vast majority were mild to moderate and diminished over time, consistent with the GLP-1 receptor agonist class.


https://finance.yahoo.com/news/novo-nordisk-semaglutide-7-2-121100240.html

Ozempic, Wegovy Selected For Next Round Of Medicare Drug Price Negotiations

 On Friday, the U.S. Department of Health and Human Services (HHS) unveiled the selection of 15 additional drugs covered under Medicare Part D for price negotiations, building on efforts to reduce prescription drug costs.

These negotiations, mandated by the Inflation Reduction Act, will take place in 2025, with the new prices slated to take effect in 2027.


The selected drugs, used to treat conditions like cancer, diabetes, and asthma, represented approximately $41 billion in Medicare Part D costs between November 2023 and October 2024, accounting for 14% of the program's total expenses.

Under the finalized guidance for the second negotiation cycle, drug manufacturers have until February 28, 2025, to decide on their participation.

The selected drug list for the second cycle of negotiations is:

  • Novo Nordisk's (NYSE:NVO) diabetes and weight loss drugs, Ozempic, Rybelsus, and Wegovy.

  • Pfizer Inc.'s (NYSE:PFE) Ibrance for breast cancer and Xtandi for prostate cancer.

  • GSK Plc's (NYSE:GSK) Asthma and Chronic obstructive pulmonary disease treatment Trelegy Ellipta and Breo Ellipta.

  • Teva Pharmaceutical Industries Ltd.'s (NYSE:TEVA) Huntington's disease and Tardive dyskinesia drug Austedo, Austedo XR.

  • Abbvie Inc.'s (NYSE:ABBV) irritable bowel syndrome treatment Linzess and depression drug Vraylar.

  • Bristol-Myers Squibb Co's (NYSE:BMY) Pomalyst for a type of blood cancer.

  • Boehringer Ingelheim's lung disease drug Ofev and diabetes med Tradjenta.

  • AstraZeneca Plc’s (NASDAQ:AZN) cancer drug Calquence

  • Salix Pharmaceuticals' irritable bowel syndrome drug Xifaxan

  • Merck & Co Inc's (NYSE:MRK) diabetes drug Janumet; Janumet XR.

  • Amgen Inc's (NASDAQ:AMGN) psoriasis drug Otezla

  • CMS will evaluate factors such as the drug's clinical benefit, its role in addressing unmet medical needs, and its impact on specific populations, alongside considerations for research, production, and distribution costs.

    The first negotiation cycle in 2023 resulted in agreements for price reductions on 10 drugs, with discounts ranging from 38% to 79% off list prices.

    The new prices, effective January 2026, are expected to save $6 billion in prescription drug costs annually and reduce out-of-pocket expenses for Medicare beneficiaries by an estimated $1.5 billion.

    Looking ahead, CMS plans to expand the program, selecting up to 15 additional drugs for the third cycle and 20 more in subsequent cycles.

  • The Inflation Reduction Act also introduces an out-of-pocket cap of $2,000 for Medicare Part D enrollees starting in 2025. Approximately 11 million beneficiaries are expected to benefit from the cap, saving a projected $7.2 billion annually.

  • https://finance.yahoo.com/news/popular-ozempic-wegovy-selected-next-171520498.html

Ventas upped to Outperform from Neutral by Baird

Target to $65 from $66

https://finviz.com/quote.ashx?t=VTR&ty=c&ta=1&p=d

Revance Therapeutics soars after Crown Labs raises offer to $3.65 a share

 Revance Therapeutics (NASDAQ:RVNC) jumped 11% in premarket trading after Crown Laboratories increased its offer above Teoxane's latest bid.

Crown Labs increased its offer to $3.65 a share, above Teoxane's $3.60 bid, according to a proxy fling on Friday.

The increased offer comes after Revance (NASDAQ:RVNC) last Wednesday said it planned to enter talks  with Teoxane after its board said that its bid is likely to be superior to Crown Labs. Teoxane offered to purchase Revance (RVNC) for $3.60 a share in cash, above Crown's $3.10 a share deal. 

Teoxane made its bid after Revance (RVNC) shares tumbled 21% on Dec. 9 after the company agreed to a revised deal with Crown Labs, with the takeover price cut by more than half from its original $6.66 a share deal agreement.

https://www.msn.com/en-us/money/topstocks/revance-therapeutics-soars-after-crown-labs-raises-offer-to-3-65-a-share/ar-AA1xnoAG

Astrazeneca CALQUENCE plus chemo OKd formantle cell lymphoma

 Based on ECHO Phase III trial results which showed more than 16 months of progression-free survival improvement vs. chemoimmunotherapy alone

First and only BTK inhibitor approved for the 1st-line treatment of MCL in the US

https://www.businesswire.com/news/home/20250117223765/en/